2689
Paraplegia following prophylactic intrathecal cytosine arabinoside (Ara-C) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg/m2/d for 5 consecutive days.
 ( adverse event: following ,  a patient with acute myelogenous leukemia in remission: Subject, Paraplegia: Effect, prophylactic intrathecal cytosine arabinoside (Ara-C): Treatment, doses of 100 mg/m2/d for 5 consecutive days: Treatment, cytosine arabinoside: Treatment.Drug, intrathecal: Treatment.Route, acute myelogenous leukemia in remission: Treatment.Disorder, 100 mg/m2/d: Treatment.Dosage, 5 consecutive days: Treatment.Duration) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( adverse event: following ,  a patient with acute myelogenous leukemia in remission: Subject, Paraplegia: Effect, prophylactic intrathecal cytosine arabinoside (Ara-C): Treatment, doses of 100 mg/m2/d for 5 consecutive days: Treatment, cytosine arabinoside: Treatment.Drug, intrathecal: Treatment.Route, acute myelogenous leukemia in remission: Treatment.Disorder, 100 mg/m2/d: Treatment.Dosage, 5 consecutive days: Treatment.Duration) 